AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 121 min read$REPL

Xynos Konstantinos sold $148K of REPL

Xynos Konstantinos (Chief Medical Officer) sold 11,447 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.15M total) on 2026-08-10.

Original reporting
SEC EDGAR · Xynos Konstantinos
Published Aug 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior (CMO selling 11,447 shares) but no new company fundamentals, guidance, or regulatory/clinical milestones.

02

Market read

Traders may monitor insider activity, but the disclosure alone is unlikely to drive a durable repricing without corroborating fundamental news.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing does not indicate intent to change strategy or company outlook.

Relevance 4/10Novelty 3/10Timing: filed Aug 12, covering a sale executed Aug 10

Background

The article is a SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group disclosed an insider open-market sale by CMO Xynos Konstantinos of 11,447 shares at $12.97 on Aug 10.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider transactions are common and typically not predictive without accompanying company-specific news; the article provides sale size, price, and post-transaction holdings only.

Market effects

Sector

Minimal, as this is company-specific insider selling with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan could be interpreted as less “pre-scheduled” selling, which some traders may read as near-term caution.

Key entities

  • issuer
    Replimune Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Xynos Konstantinos

    Chief Medical Officer who sold shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REPL insider trading history →

Related articles

OCT 1
$REPLHighAI 8/10

Replimune launches melanoma therapy in US market

Replimune Group Inc. (REPL) announced the U.S. commercial launch of TUDRIQEV, a melanoma therapy for advanced cutaneous melanoma patients who progressed on PD-1-blocking treatments. The FDA granted accelerated approval based on a 24.2% objective response rate in trials. The company estimates 105,000 new U.S. melanoma cases in 2025. Continued approval depends on confirmatory trial results.

investing.com2 min
OCT 1
$REPLHighAI 8/10

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

Replimune Group, Inc. (REPL) announced that TUDRIQEV™, a treatment for advanced melanoma, is now available in the U.S. The therapy, approved under accelerated approval, is indicated for adult patients who have progressed with PD-1-blocking antibody regimens. TUDRIQEV achieved a 24.2% objective response rate in clinical trials, with a median duration of 14.1 months. The company also launched a patient support program to assist with access and reimbursement.

globenewswire.com2 min
SEP 21
HighAI 9/10

Citing Replimune approval, experts say localized cancer meds could redefine care

Replimune's recent approval for Tudriqev, a melanoma immunotherapy, may signal a shift in early-stage cancer treatment. Experts highlight the potential of locally delivered therapies, with BMO Capital Markets estimating $1.3B annual sales for Tudriqev by 2035. Companies like Surge Therapeutics, Johnson & Johnson, and Ankyra Therapeutics are advancing similar treatments, aiming to improve efficacy and reduce toxicity.

biospace.com3 min
SEP 11
$MRNAHighAI 9/10

New FDA Drug Approvals - August 2026

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

finanznachrichten.de3 min
SEP 11
$REPLHighAI 8/10

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

Replimune Group (REPL) stock surged 140% in pre-market trading after a favorable FDA advisory committee review of its melanoma therapy RP1. Cantor Fitzgerald upgraded REPL to 'Overweight' from 'Neutral', citing an 'overwhelmingly positive' panel outcome. The FDA is expected to make a final decision by Aug. 2, 2026. REPL's stock has fallen 39% year-to-date.

stocktwits.com2 min